Intravitreal anti-VEGF therapy is routinely used for various retinal conditions, including wet age-related macular degeneration (AMD) [1,2], retinal vein occlusion, myopic choroidal neovascularization, and diabetic retinopathy [3]. Here, VEGFA is linked to wet macular degeneration.